Testing two drugs after focused radiation for lymphoma in the brain and spinal cord
Official title: Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether two drugs given after focused radiation are safe and helpful for people with lymphoma in the brain or spinal cord.
Read our full plain-language summary
What the trial team says
The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.
Key facts
- Registry number
- NCT06607549
- Stage of testing
- Phase 1
- Conditions studied
- Central Nervous System Lymphoma
Where it is running
This trial lists 3 sites.
-
Pennsylvania
- Sidney Kimmel Comprehensive Cancer Center at Jefferson (Philadelphia)
-
Rhode Island
- Brown University Health Rhode Island Hospital (Providence)
-
Utah
- Huntsman Cancer Institute at University of Utah (Salt Lake City)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.